UTv Videos

“In addition to having a well-rounded urology residency experience, where you're gaining surgical exposure to all the different aspects of urology, I think it's really important to add on and delve into a fellowship in gender affirming surgery,” says Geolani Dy, MD.

“Physicians should take better care of their own personal needs [and] create some boundaries…for a more balanced life,” says William Lynes, MD.

“I believe we are getting to an era where we will be able to cure a significant subset of patients who we are not able to cure today,” says Neil H. Bander, MD.

“The decrease of frequency in doing these procedures may not put improving the techniques of the procedure at the forefront of the surgeon's mind,” says Svetlana Avulova, MD.

“[Kidney stones] really seems like something that we should be devoting significant resources and effort to trying to figure out the root causes and also better treatments and therapies for,” says Jonathan E. Shoag, MD.

“We should really try to adapt, know what we're doing to the specific patient based on their risk factors, prepare them appropriately, and understand that it's a dangerous complication. We should do everything we can to prevent it,” says Naeem Bhojani, MD, FRCSC.

“Take care of yourself, so we can take care of other people,” says Diana Londoño, MD.

“I believe that this is, of course,…a harbinger of what is to come—those of underserved backgrounds being…featured [more] in our organizations,” says Curtis A. Pettaway, MD.

“There is a whole range of ways in which urologists are involved in gender-affirming care,” says Geolani Dy, MD.

“We will also cover options for germline testing—different ways that tests can be ordered, panel options that are available commercially,” says Veda N. Giri, MD.

“While this study does offer a lot of promise for the treatment options that we can offer to these patients, it does also highlight the need for further prospective trials to evaluate the efficacy of this treatment, as well as the treatments of all the different surgical options available to patients who are suffering from BPH,” says Evan Garden.

“It is a promising drug in terms of the 3-month complete response rate,” says Chad Ritch, MD, MBA, FACS.

“I would say what RTOG-0815 has provided is data to have an intelligent conversation with our patients and provide them numbers so that they know what to expect,” says Bridget F. Koontz, MD.

“I think the key elements are that you should know about Aquablation if you are treating BPH in consideration for your patients and care, especially those who are looking for a more durable response and to maintain their ejaculation,” says Kevin Zorn, MD, FRCSC, FACS.

“New things are being developed and, I believe, at the moment showing great initiative and resolve,” says Justin Chee, MD.

“We need better tests and better biomarkers to try to determine who still has residual cancer, even though they look like they don't,” says Christopher B. Anderson, MD, MPH.

Welcome to another installment of Uranimals, our video series featuring urologists and their pets. From a dog duo to a group of animals living mountainside, check out our latest guests!

“Our preclinical therapy models all show us that the combination of the 2 agents [alpha and beta particles] is substantially superior to either agent alone,” says Neil H. Bander, MD.

“Thirteen percent of all doctors have suicidal ideation, and more than [400 physicians per year] will complete suicide. That is a tragedy of medicine,” says Diana Londoño, MD.

“I believe that at every stage, it's very important that we focus on healthful lifestyle behaviors because we can improve [urologic patients’] overall survival and their cardiovascular health,” says Stacy Loeb, MD, PhD, MSc.

“Compared to other BPH treatments, this is a very fast, reproducible technology that could democratize how all urologists do BPH surgery,” says Kevin Zorn, MD, FRCSC, FACS.

“It was black, it was overwhelming, it was every day,” says William Lynes, MD.

“Completing those 4 injection cycles is likely to yield the best clinical outcomes for most of our patients,” says Matthew J. Ziegelmann, MD.

“Men do well and they don't have a really high risk of outcomes that we don't want them to have and that patients don't want to have, which is really the need to catheterize,” says David A. Ginsberg, MD.

“Sepsis is real, and it's around 5%. I was surprised too, but this is what the actual data shows, and we should be aware of it,” says Ben H. Chew, MD, MSc.

“It's very clear that PSMA-PET imaging is having…a transformative impact on our ability to image metastatic disease, in that it is much more sensitive than we've had for the last 50 plus years—and also, 98% specific,” says Neil H. Bander, MD.

“We hope to further investigate next-generation PSMA-targeting molecules, develop new biomarkers to try to predict and monitor response to these novel therapies, optimize combinations with other treatments, and do some discovery research, including artificial intelligence [and] deep learning of our images,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.

“We expect an outcome from the FDA next year and if that's positive, we expect global, widespread availability of this as a new option for men with metastatic castration-resistant prostate cancer,” says Michael S. Hofman, MBBS (Hons), FRACP, FAANMS, FICIS.